ERBB2 and breast carcinoma: In HER2-negative breast cancer patients, adjuvant therapy combining NOV-002 with doxorubicin, cyclophosphamide, and docetaxel chemotherapy improved clinical outcomes with reduced treatment-related toxicity compared to chemotherapy alone [397].